Ethinyl estradiol and desogestrel and Granisetron Hydrochloride

• Generic Name: desogestrel / ethinyl estradiol
• Dosage Forms: n.a.
• Other Brand Names: Azurette, Cyclessa, Desogen, Isibloom, Kariva, Mircette, Reclipsen, Cyred

Ethinyl estradiol and desogestrel is a combination birth control pill containing female hormones that prevent ovulation (the release of an egg from an ovary). ethinyl estradiol and desogestrel also causes changes in your cervical mucus and uterine lining, making it harder for sperm to reach the uterus and harder for a fertilized egg to attach to the uterus.

Ethinyl estradiol and desogestrel is used to prevent pregnancy. There are many brands of this medicine available. Not all brands are listed on this leaflet.

Ethinyl estradiol and desogestrel may also be used for purposes not listed in this medication guide.

• Generic Name: granisetron
• Dosage Forms: n.a.
• Other Brand Names: Kytril, Sustol, Sancuso

Prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin.

For prevention of nausea and vomiting associated with highly emetogenic chemotherapy regimens (including an anthracycline plus cyclophosphamide), ASCO recommends a 3-drug antiemetic regimen consisting of an NK1 receptor antagonist (e.g., either oral aprepitant or IV fosaprepitant), a 5-HT3 receptor antagonist (e.g., dolasetron, granisetron, ondansetron, palonosetron), and dexamethasone. ASCO states that fixed-combination netupitant and palonosetron plus dexamethasone is an additional treatment option.

For moderately emetogenic chemotherapy regimens, ASCO recommends a 2-drug antiemetic regimen preferably consisting of palonosetron and dexamethasone. If palonosetron is not available, a first-generation 5-HT3 receptor antagonist (preferably granisetron or ondansetron) may be substituted. Limited evidence suggests that aprepitant may be added to this regimen; in such cases, use of any 5-HT3 receptor antagonist is appropriate.

For chemotherapy regimens with a low emetogenic risk, ASCO recommends administration of a single dose of dexamethasone prior to chemotherapy.

For chemotherapy regimens with minimal emetogenic risk, ASCO states that routine antiemetic administration is not necessary.

Prevention and treatment of postoperative nausea and vomiting.

Routine prophylaxis not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively.

Recommended for patients who, in the clinician’s judgment, must avoid nausea and/or vomiting postoperatively, even when anticipated incidence is low.

Prevention of nausea and vomiting associated with radiation, including total body irradiation and daily fractionated abdominal radiation.